Introduction
============

Statins are HMG-CoA reductase inhibitors that interfere with cholesterol biosynthesis and are thus extensively used in the treatment of hypercholesterolemia. Statins have various pleiotropic effects that are independent of their serum cholestrol-lowering properties. Some of those reported have included antioxidative, anti-inflammatory and immunomodulatory capabilities ([@B2]). Members of our group have also reported an enhanced graft longevity effect for atorvastatin, one of the most commonly used statins, in mice and in human transplant recipients; this is potentially due to atorvastatin's immunomodulatory properties ([@B11]; [@B37],[@B38]; [@B59]).

A number of studies have indicated that statins may also have beneficial effects as therapeutic agents in infection and sepsis as well as prophylactic agents that reduce the risk of infection. On the other hand, some studies have shown no beneficial effects or even an increased risk of an unfavorable infection outcome. Moreover, a considerable number of meta-analyses and systematic reviews have examined the literature on statins and infection with rather inconclusive results ([@B12]; [@B14]; [@B19]; [@B50], [@B49]; [@B3]; [@B16]; [@B51]; [@B27]; [@B52]; [@B53]).

Multiple reports indicate that statins have anti-inflammatory and immunomodulatory properties affecting both Th1 and Th2 immune responses ([@B23]; [@B30]; [@B36]). Statins were demonstrated to interfere with the proliferation and activation of a myriad of immune cell types ([@B10]; [@B4]; [@B56]; [@B17]; [@B44]). Moreover, the expression of a considerable number of cytokines ([@B55]; [@B26]), adhesion molecules and class II human leukocyte antigens (HLA) ([@B21]) was shown to be downregulated by statins ([@B42]; [@B20]; [@B40]; [@B54]). On the other hand, statins appear to decrease the expression of cyclooxygenase-2 (COX-2) ([@B57]) while potentially triggering the expression of the rather anti-inflammatory Heme-oxygenase-1 (HO-1) enzyme ([@B33]). Furthermore, statins may modulate inflammatory responses by interfering with nuclear factor kappa B (NFkB) ([@B54]), peroxisome proliferator activated receptors (PPAR) and mitogen-activated protein kinase (MAPK) signaling ([@B18]) among other pathways.

Our group has previously reported a suppression of certain aspects of both the humoral and the cell-mediated branches of immunity in mice challenged with egg albumin upon treatment with atorvastatin ([@B11]). We detected a suppression of IFN-γ and IL-4 production. Therefore, a potential protective effect of statins against infection, as indicated above, in light of its immunosuppressive properties is at first glance rather counterintuitive. Hence, we investigated the effects of atorvastatin on the immune status and on the survival of mice during a fungal infection. The antifungal properties of statins are rather well-documented; various mechanisms that relate to inhibition of ergosterol and isoprenoid-biosynthesis are thought to result in these antifungal properties. Various statins have been reported to inhibit the growth of *Aspergillus* ([@B28]; [@B57]), Zygomycete ([@B43]), *Cryptococcus* ([@B7]), and *Candida* species including *Candida albicans* ([@B7]; [@B46]). Mechanisms behind statin-mediated inhibition of fungal growth probably vary between different species. For example, lovastatin-mediated genetic inhibition of siderophore triacetylfusarinine C (TAFC), required for iron uptake in *Aspergillus fumigatus*, results in attenuated virulence in this organism. This implies that statin treatment might affect virulence of *A. fumigatus* also via inhibition of TAFC biosynthesis and not solely via inhibition of isoprenoide biosynthesis. This mechanism is not expected to play a role in fungal species that rely on non-HMGCoA reductase-dependent siderophores or that do not produce siderophores such as *C. albicans* and *Cryptococcus neoformans* ([@B57]).

We intended to evaluate whether the immunosuppressive effects of atorvastatin outweighed its anti-fungal effects. For this purpose BALB/c mice were infected with *C. albicans*. Mouse survival was then monitored. Additionally, IFN-γ and IL-4 were examined in these mice to assess pro-inflammatory and pro-humoral responses, respectively.

Materials and Methods {#s1}
=====================

Atorvastatin and *C. albicans*
------------------------------

Lipitor^®^ (Pfizer Inc., New York, NY, USA) tablets, each containing 10 mg of atorvastatin, were pulverized and suspended in phosphate buffered saline (PBS) (Sigma--Aldrich, St. Louis, MO, USA). The *C. albicans* American Type Culture Collection (ATCC) 14053 strain was used in this study. *In vitro* susceptibility of this strain to atorvastatin was verified using Clinical Laboratory Standards Institute (CLSI) guidelines.

Mouse Treatments and Survival Monitoring
----------------------------------------

Mouse studies were approved by the Institutional Animal Care and Use Committee (IACUC) at the American University of Beirut prior to initiation of experiments. Five groups of 4--6 weeks old BALB/c mice, each containing 9 animals, were used to monitor survival upon atorvastatin treatment and infection. One group was infected with *C. albicans* receiving a co-injection of atorvastatin, a second group received one injection of atorvastatin per day for 5 days prior to infection with *C. albicans* and a third group was infected with *C. albicans* then treated with one injection of atorvastatin for 5 days afterward. A group that was not treated with atorvastatin but received a single dose of *C. albicans* was included. In addition a group that received a single injection of PBS on the day of infection was used as a negative control since PBS was used to prepare *C. albicans* and atorvastatin doses. Mice infected with *C. albicans* were injected with 10.8 × 10^7^ colony forming units (CFUs) intraperitoneally; this infectious dose was selected since it was sub-LD50 when injected intraperitoneally into BALB/c mice and allowed for monitoring a variation in death events upon atorvastatin treatment. Atorvastatin injections were also administered intraperitoneally with each injection consisting of 40 mg/Kg, the minimum effective immunomodulatory dose in BALB/c mice as reported in our previous studies ([@B11]). Atorvastatin, *C. albicans* and PBS injections each consisted of 0.25 ml. Infected mice were then monitored for 18 days. Upon mouse death, the liver, spleen and heart were collected, homogenized and cultured to verify that death was due to systemic infection with *C. albicans*.

Determination of Mouse Serum IFN-γ and IL-4 Levels
--------------------------------------------------

To assess mouse serum IFN-γ and IL-4 levels, a set of mice was treated as described above for survival monitoring; however, three mice per group were sacrificed by cardiac puncture on day 3 post-*C. albicans* infection. This day was selected for cytokine assessment since it occurred 1 day prior to escalation of death events. Three mice from the PBS-treated group were also sacrificed on day 3 post-injection. Sera were pooled per group and analyzed for cytokine levels with Single Analyte ELISArray Kits (Qiagen Inc., Valencia, CA, USA).

Statistical Analysis
--------------------

The log-rank (Mantel-Cox) test and Kaplan--Meier survival analysis were conducted using PASW Statistics 18 for Windows. Two-sample *t*-tests were used to assess cytokine level variations with the GraphPad *t*-test calculator. Mouse groups infected with *C. albicans* and treated with atorvastatin were compared to the mouse group infected with *C. albicans* but not treated with atorvastatin. *p*-values less than 0.05 were considered statistically significant.

Results
=======

Mouse Survival
--------------

In *C. albicans*-infected mice, survival analysis (*p* \< 0.05, individual treated groups compared to the infected but untreated group) revealed that the lowest survival rate at the end of the monitoring period was 11.1%, observed in the group treated for 5 days pre-infection with atorvastatin (**Figure [1](#F1){ref-type="fig"}**). The survival rate at the end of the monitoring period in the group treated for 5 days post-infection with atorvatstatin was 22.2% while it was 44.4% in the group of mice that received a single dose of atorvastatin along with infection. The survival rate of the group infected with *C. albicans* but not treated with atorvastatin was 44.4%. Mouse death due to *C. albicans* infection was verified via recovering the organism from mouse liver, spleen, and heart by culture; no notable differences in fungal burden were detected between the statin treated groups and the untreated group upon culturing the indicated organs.

![**Cumulative survival of mice infected with *Candida albicans* and treated with atorvastatin.** BALB/c mice received an injection of *C. albicans* and were treated either with a single co-injection of atorvastatin, 5 days pre-infection or a 5 days post-infection atorvastatin regimen. A group infected with *C. albicans* but not treated with atorvastatin was also included. A mouse group injected solely with PBS, as a negative control, showed a 100% survival rate (not shown). Day 0 indicates the day of infection. Mice were monitored for 18 days after infection.](fmicb-06-01474-g001){#F1}

### Mouse Serum IFN-γ and IL-4

Mouse groups infected with *C. albicans* and treated with atorvastatin showed a 95-fold decrease in the levels of IFN-γ on day 3 post-infection compared to the group infected but not treated with atorvastatin (**Figure [2](#F2){ref-type="fig"}**).

![**Serum IFN-γ levels in mice infected with *C. albicans* and treated with atorvastatin.** BALB/c mice received an injection of *C. albicans* and were treated either with a single co-injection of atorvastatin, 5 days pre-infection or a 5 days post-infection atorvastatin regimen. A group that was infected with *C. albicans* but not treated with atorvastatin was included in addition to a group injected solely with PBS, as a negative control. Mouse sera were then assessed for IFN-γ levels by ELISA on day 3 post infection. ^∗^ indicates *p* \< 0.05 compared to the *C. albicans*-infected group.](fmicb-06-01474-g002){#F2}

All mouse groups infected with *C. albicans* and treated with atorvastatin showed a suppressed level of serum IL-4 (**Figure [3](#F3){ref-type="fig"}**). Mice infected with *C. albicans* and treated with atorvastatin displayed a 2222-fold decrease in the level of this mediator on day 3 post-infection compared to mice infected with *C. albicans* but not treated with atorvastatin.

![**Serum IL-4 levels in mice infected with *C. albicans* and treated with atorvastatin.** BALB/c mice received an injection of *C. albicans* and were treated either with a single co-injection of atorvastatin, 5 days pre-infection or 5 days post-infection atorvastatin regimen. A group that was infected with *C. albicans* but not treated with atorvastatin was included in addition to a group injected solely with PBS, as a negative control. Mouse sera were then assessed for IL-4 levels by ELISA on day 3 post infection. ^∗^ indicates *p* \< 0.05 compared to the *C. albicans*-infected group.](fmicb-06-01474-g003){#F3}

Discussion
==========

Various antimicrobial and immunomodulatory effects have been described for the statins class of antihyperlipidemia drugs. In addition, several studies have indicated clinical benefits for the use of statins during the management of infections and sepsis in human subjects. We therefore used a mouse model of fungal infection to assess whether the previously described immunosuppressive effects of statins outweigh their anti-microbial effects during an infection. In particular, we examined the effects of atorvastatin, one of the most commonly prescribed statins.

We observed that treatment of *C. albicans*-infected mice with atorvastatin was capable of decreasing survival depending on the regimen employed. IFN-γ and IL-4 levels were suppressed by atorvastatin treatment independent of the treatment mode. We did not detect any notable differences in fungal burden between the statin treated groups and the untreated group upon culturing harvested organs; this may indicate that the immunosuppressive effects detected were sufficient to overcome the antifungal properties of the atorvastatin. Higher doses of atorvastatin may have allowed better tissue distribution and prevented organism proliferation within organ tissues; however, such doses would have been outside of the range used for therapy in humans.

In our previous studies on BALB/c mice atorvastatin reduced the expression of IFN-γ when mice were challenged with albumin ([@B11]) but not when they received skin allografts from C57BL/6 mice ([@B59]). Hence, a decrease of IFN-γ may be dependent on the challenge itself and whether it can overcome atorvastatin suppression. For example, in a study investigating the *in vitro* role of fluvastatin in *Mycobacterium tuberculosis* infection in human peripheral blood mononuclear cells, fluvastatin was found to enhance the Th1 protective response to the infection ([@B34]). The proposed mechanism for this effect was an increased activity of Caspase I. This protease converts pro-IL-1β and -18 into their biologically active forms, which in turn act synergistically with IL-12 to induce IFN-γ release; this study found that fluvastatin, in the presence of an *M. tuberculosis* infection, enhances the activity of Caspase I, ultimately leading to an increase in IFN-γ production and therefore giving the immune response a Th1 bias. It has also been shown that statins, including atorvastatin, repress the expression of MHC II molecules induced by IFN-γ, thereby impairing T-cell activation and compromising the adaptive immune response ([@B21]). Moreover, simvastatin was shown to suppress the expression of Toll-like receptor (TLR) 4 on human monocytes *in vivo* in response to LPS treatment; this was associated with reduced tumor necrosis factor-α and monocyte chemoattractant protein-1 levels ([@B35]). A similar effect was also observed in human CD14+ monocytes treated with atorvastatin, whereby TLR 4 expression was significantly down-regulated ([@B32]). Hence, upon atorvastatin treatment, whether IFN-γ levels rise or are suppressed in response to a challenge, other aspects of the immune response, including those downstream to IFN-γ, may be impaired. This would result in an inadequate immune response.

All groups treated with atorvastatin had a severe decrease in the levels of the assessed cytokines regardless of the mode of treatment. This corresponded with decreased survival rates in groups of mice treated with atorvastatin for 5 days before or after infection. This indicates that the enhanced death is likely due to the immunosuppressive effects of this agent overcoming its anti-fungal effects. On the other hand, despite the decrease in detection of IFN-γ and IL-4 in the group of mice receiving a single dose of atorvastatin along with infection, death rates were not enhanced in this group. This may indicate that other components of the immune system are affected by a prolonged treatment with atorvastatin resulting in the enhanced death rates seen in the groups of mice treated for 5 days with atorvastatin before or after infection. Components of the immune response previously reported to play major roles in combating *C. albicans* infections that may have been affected by this prolonged treatment include Th17 and neutrophil responses. Multiple studies indicate that these components are modulated by statin treatment. Pravastatin, simvastatin, and atorvastatin were shown to reduce neutrophil transendothelial migration ([@B29]) and lovastatin was reported to affect leukocyte mobilization and result in a Th1 to Th2 shift in a heat-inactivated *Candida albicans* delayed type hypersensitivity mouse model ([@B33]). Moreover, simvastatin was demonstrated to enhance neutrophil apoptosis ([@B6]). Atorvastatin, among other statins, was also shown to decrease Th17 responses in various models and in humans ([@B1]; [@B24]; [@B15]; [@B22]). Although the survival rate of the group receiving a single injection of atorvastatin along with infection was similar to the group that received the infection alone by the end of the monitoring period, the death events in the former group occurred at a slower pace. This may indicate that the atorvastatin anti-microbial properties have an effect at this dose that is ultimately insufficient or eventually overwhelmed by the immunosupressed state of the mice.

Worth noting is that the dose of each atorvastatin injection administered to mice in the study at hand, 40 mg/Kg, is equivalent to a dose of 3.24 mg/Kg in man based on United States Food and Drug Administration (FDA) mouse to human dose translation guidelines ([@B39]). This dose is therefore about 2.5X that currently recommended per day for the treatment of most human subjects. We used this dose since it was the lowest to have an immunomodulatory effect in BALB/c mice in our previous studies ([@B11]). Moreover, these previous studies have shown that this dose of atorvastatin is not lethal to the mice by itself. While the dose we employed is higher than the one typically employed in man, similar high daily doses have been used in some subject groups ([@B8]) and multi-dosing has been reported to result in cumulative blood level spikes ([@B25]).

A decrease in sepsis-associated mortality rate in human subjects on statins was presumed to be an effect of the immunomodulatory and anti-inflammatory properties of these drugs. In murine models ([@B31]; [@B58]; [@B5]; [@B41]; [@B45]), statins appeared to improve animal survival rates after septic shock induced by LPS challenge, bacterial infection or cecal ligation and puncture and pravastatin has been shown to enhance the survival of *C. albicans*- challenged mice ([@B48]). [@B5] have demonstrated that mice challenged with LPS have significantly lower serum TNF-α and IL-6, the pro-inflammatory cytokines, upon cerivastatin treatment. On the other hand, animals challenged with live *Staphylococcus aureus* or *Salmonella enterica* serovar Typhimurium did not display a significant decrease in TNF-α or IL-6 levels after treatment.

Although some studies have described potential benefits for statin use during a *Candida* infection both in mice ([@B48]) and in a clinical setting ([@B13]; [@B47]; [@B9]), our findings added to the observations denoted above indicate that the effects of statins may be dependent on the type of infection and the agent administered itself in addition to the statin regimen employed. The study by [@B48], indicated above, reported enhanced survival and a decreased fungal burden in C3H/HeN mice infected with *C. albicans* treated with pravastatin. We did not see a similar effect in BALB/c mice treated with atorvastatin. This underscores the notion that different statins may result in different outcomes potentially in a host and regimen-dependent manner. Further studies will tackle mechanisms upstream of cytokine level modulation that are differently affected in a challenge-dependent manner upon statin treatment. Prominent candidates for examination are members of the TLR family of receptors, some of the first responders that recognize non-host molecules; as described above, evidence indicates that TLR molecules may be affected by statin treatment which rather brings them to the forefront. Moreover, cellular responses downstream of the assessed cytokines resulting in decreased animal survival should also be examined. Therefore, statins are potentially deleterious to the health and survival of a subject during an infection. Their administration may suppress or modulate particular components of the immune system. This possibility should be taken into account and further explored in large randomized controlled trials.
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